Pharmacology & Toxicology
1996-08-01
The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene.
K Kristensen, C B Christensen, L L Christrup, L C Nielsen
文献索引：Pharmacol. Toxicol. 79(2) , 103-4, (1996)
全文：HTML全文
摘要
相关文献：
Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
1981-02-01
[Eur. J. Clin. Pharmacol. 19(3) , 217-23, (1981)]
Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.
1998-03-01
[Pharmacol. Toxicol. 82(3) , 157-60, (1998)]
Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
1988-01-01
[Acta Oncol. 27(5) , 583-9, (1988)]
Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine.
1986-10-01
[Acta Anaesthesiol. Scand. 30(7) , 502-6, (1986)]
Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
1982-01-01
[Acta Pharmacol. Toxicol. (Copenh.) 50(1) , 78-80, (1982)]